Senti Biosciences (SNTI) to Release Quarterly Earnings on Tuesday

Senti Biosciences (NASDAQ:SNTI) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $0.0210 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 9:30 AM ET.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $1.00 million. On average, analysts expect Senti Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Senti Biosciences Stock Down 9.5%

Shares of Senti Biosciences stock traded down $0.10 during trading hours on Tuesday, reaching $0.96. 145,085 shares of the stock traded hands, compared to its average volume of 193,296. The company has a 50 day moving average price of $0.94 and a 200 day moving average price of $1.30. The firm has a market capitalization of $29.87 million, a price-to-earnings ratio of -0.30 and a beta of 2.11. Senti Biosciences has a one year low of $0.77 and a one year high of $3.88.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SNTI shares. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Chardan Capital cut their price objective on Senti Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SNTI. Geode Capital Management LLC grew its stake in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the period. Armistice Capital LLC bought a new position in Senti Biosciences in the 2nd quarter worth approximately $1,883,000. Citadel Advisors LLC bought a new position in Senti Biosciences in the 3rd quarter worth approximately $117,000. Jane Street Group LLC bought a new position in Senti Biosciences in the 4th quarter worth approximately $40,000. Finally, Virtu Financial LLC bought a new position in Senti Biosciences in the 4th quarter worth approximately $46,000. 25.70% of the stock is currently owned by institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.